{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1"},{"groupId":"OG001","value":"62.5"},{"groupId":"OG002","value":"23.5"},{"groupId":"OG003","value":"3.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"30"}],"units":"Participants"}],"description":"Participants with newly diagnosed Hairy Cell Leukemia (HCL) and once relapsed HCL were split and both groups were randomized to receive either simultaneous treatment with Cladribine and Rituxan or Cladribine with Rituxan given no earlier than 6 months after cladribine as needed. Outcome measured by Bone Marrow and Blood Flow cytometry and histochemistry of the core biopsy at the 6 months after start of treatment time point. If all three were negative for hairy cells participants were in a minimal residual disease status (MRD). And were considered without HCL disease at that time point.","groups":[{"description":"Participants with Hairy Cell Leukemia (HCL) with (62 participants) and without (68 participants) prior course of purine analog to be randomized between Arm 1 and Arm 2 (randomization stratified based upon prior purine analog \\[yes/no\\]). Cladribine + Rituximab.","id":"OG000","title":"Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab"},{"description":"Participants with Hairy Cell Leukemia (HCL) with (62 participants) and without (68 participants) prior course of purine analog to be randomized between Arm 1 and Arm 2 (randomization stratified based upon prior purine analog \\[yes/no\\]). Cladribine + Rituximab.","id":"OG001","title":"Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab"},{"description":"Participants with Hairy Cell Leukemia (HCL) with (62 participants) and without (68 participants) prior course of purine analog to be randomized between Arm 1 and Arm 2 (randomization stratified based upon prior purine analog \\[yes/no\\]). Cladribine (+ Rituximab after 6 months if minimal residual disease (MRD) detected).","id":"OG002","title":"Cohort 1 Arm 2 SubGroup 1-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected)"},{"description":"Participants with Hairy Cell Leukemia (HCL) with (62 participants) and without (68 participants) prior course of purine analog to be randomized between Arm 1 and Arm 2 (randomization stratified based upon prior purine analog \\[yes/no\\]). Cladribine (+ Rituximab after 6 months if minimal residual disease (MRD) detected).","id":"OG003","title":"Cohort 1 Arm 2 SubGroup 2-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected)"}],"paramType":"NUMBER","populationDescription":"Cohort 2, Arm 3 and Cohort 3, Arm 3 are not reported because the investigator is only comparing the randomized groups. The primary goal is comparing the randomization and Cohort 2 was not randomized.","reportingStatus":"POSTED","timeFrame":"Restaged 6 months after the start of treatment","title":"Response Rate Comparing Minimal Residual Disease (MRD) at 6 Months After Start of Treatment in Comparison Groups","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}